Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed
Ultragenyx shares fell 42% to $19.72 after its drug setrusumab failed to meet the main fracture-reduction goal in two Phase 3 trials for osteogenesis imperfecta. The company announced plans to cut expenses. Citi reduced its price target to $50 but maintained a Buy rating.